Sutro’s Chinese partnership They manage to strike a decent deal after their Phase1a. They did show efficacy but also their drug destroyed quite substantial amount of blood white cells. They had neutropenia related mortality and one can only assume despite all the safety issues the Chinese were still interested. Point is for late stage cancers it seems like the bar is lower in terms of results. It makes me think targeted delivery specifically PDC technology with some clinical advantages versus ADCs( smaller molecules, solubility, easier/cheaper to manufacture..)could attract quite a bit of interest from potential partners.